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Editorials
n 2005, the International Committee of Medical Journal
Editors (ICMJE) initiated a policy requiring investigators to
deposit information about trial design into an accepted clinical
trials registry before the onset of patient enrolment.1 This policy
aimed to ensure that information about the existence and design of
clinically directive trials was publicly available, an ideal that
leaders in evidence-based medicine have advocated for decades.2
The policy precipitated much angst among research investigators
and sponsors, who feared that registration would be burdensome
and would stifle competition. Yet, the response to this policy has
been overwhelming. The ICMJE promised to re-evaluate the policy
2 years after implementation. Here, we summarise that re-evalua-
tion, specifically commenting on registries that meet the policy
requirements, the types of studies that require registration, and the
registration of trial results. As is always the case, the ICMJE
establishes policy only for the 12 member journals (a detailed
description of the ICMJE and its purpose is available at http://
www.icmje.org), but many other journals have adopted our initial
trial registration recommendations, and we hope that they will also
adopt the modifications discussed in this update.
The research community has embraced trial registration. Before
the ICMJE policy, ClinicalTrials.gov, the largest trial registry at the
time, contained 13 153 trials; this number climbed to 22 714 one
month after the policy went into effect.3 In April 2007, the registry
contained over 40 000 trials, with more than 200 new trial
registrations occurring weekly (D Zarin, Lister Hill National Center
for Biomedical Communications, National Library of Medicine,
National Institutes of Health, Bethesda, Md, USA, personal com-
munication). The four other registries that meet the ICMJE criteria
have also grown, as scores of journals have adopted the ICMJE
clinical trials registration policy. In response to burgeoning regis-
tration, many investigators, sponsors, and government agencies
have asked the ICMJE to recognise their local registries as data-
bases that meet the policy requirements. Fortunately, the World
Health Organization’s International Clinical Trials Registry Plat-
form (ICTRP), which was nascent when the ICMJE began to
require trial registration, has matured rapidly and provides options
for those who desire a wider array of registries. The ICTRP has
taken the first steps toward developing a network of primary and
partner registers that meet WHO-specified criteria.4 Primary regis-
ters are WHO-selected registers managed by not-for-profit entities
that will accept registrations for any interventional trials, delete
duplicate entries from their own register, and provide data directly
to the WHO. Partner registers, which will be more numerous, will
include registers that submit data to primary registers but limit
their own register to trials in a restricted area (such as a specific
disease, company, academic institution, or geographic region).
The ICMJE strongly supports the WHO’s efforts, through the
ICTRP, to develop a coordinated process for identifying, gathering,
de-duplicating, and searching trials from registries around the
world, thus eventually providing a one-stop search portal for those
seeking information about clinical trials. In addition to the five
existing registries, the ICMJE will now also accept registration in
any of the primary registers that participate in the WHO ICTRP.
Because it is critical that trial registries are independent of for-profit
interests, the ICMJE policy requires registration in a WHO primary
register rather than solely in a partner register, since for-profit
entities manage some partner registers. As previously, trial registra-
tion with missing or uninformative fields for the minimum data
elements is inadequate.1
Initially, the ICMJE required registration of all clinically directive
trials, which it defined as “any research project that prospectively
assigns human subjects to intervention or comparison groups to
study the cause-and-effect relationship between a medical inter-
vention and a health outcome”.1 In May 2005, the ICMJE clarified
this definition to exclude preliminary trials designed to study
pharmacokinetics or major unknown toxicity (phase I trials).5
However, the ICMJE recognises the potential benefit of having
information about preliminary trials in the public domain, because
these studies can guide future research or signal safety concerns.
Consequently, the ICMJE is expanding the definition of the types
of trials that must be registered to include these preliminary trials
and adopts the WHO’s definition of a clinical trial: “any research
study that prospectively assigns human participants or groups of
humans to one or more health-related interventions to evaluate the
effects on health outcomes”.4 Health-related interventions include
any intervention used to modify a biomedical or health-related
outcome (eg, drugs, surgical procedures, devices, behavioural
treatments, dietary interventions, and process-of-care changes).
Health outcomes include any biomedical or health-related meas-
ures obtained in patients or participants, including pharmacoki-
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An update on the requirements of ICMJE’s clinical trial registration policy
Key summary points
• In addition to accepting registration in any of the five existing 
registries, the International Committee of Medical Journal Editors 
(ICMJE) will accept registration of clinical trials in any of the 
primary registers that participate in the World Health 
Organization’s International Clinical Trials Registry Platform. 
Registration in a partner register only is insufficient.
• The ICMJE will begin to implement the WHO definition of clinical 
trials for all trials that begin enrolment on or after 1 July 2008. This 
definition states that a clinical trial is “any research study that 
prospectively assigns human participants or groups of humans to 
one or more health-related interventions to evaluate the effects on 
health outcomes.”
• The ICMJE will not consider results posted in the same clinical 
trials registry in which the initial registration resides to be previous 
publication if the results are presented in the form of a brief, 
structured (< 500 words) abstract or table. ◆
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netic measures and adverse events. As previously, purely
observational studies (those in which the assignment of the
medical intervention is not at the discretion of the investigator)
will not require registration. The ICMJE member journals will start
to implement the expanded definition of clinically directive trials
for all trials that begin enrolment on or after 1 July 2008. Those
who are uncertain whether their trial meets the expanded ICMJE
definition should err on the side of registration if they wish to seek
publication in an ICMJE journal.
Over the time during which registration of trial methods has
become common practice, several forces have begun advocating
for registration of trial results. We recognise that the climate for
results registration will probably change dramatically and unpre-
dictably over coming years. For the present, the ICMJE will not
consider results posted in the same primary clinical trials register
in which the initial registration resides as previous publication if
the results are presented in the form of a brief, structured (< 500
words) abstract or table. The ICMJE favours a standard abstract
format for results reporting, and the CONSORT (Consolidated
Standards of Reporting Trials) group’s forthcoming guidelines for
abstracts related to trials may be one such option. The ICMJE
believes that parties interested in results registration should con-
sider requiring the deposition of such an abstract in the registry 24
months after closure of data collection if results are not published
in a peer-reviewed venue by that time. The registered abstract
should either cite any related full, peer-reviewed publications or
include a statement that indicates that the report has not yet been
published in a peer-reviewed journal. Researchers should be aware
that editors may consider more detailed deposition of trial results
in publicly available registries to be prior publication. When
submitting a paper, authors should fully disclose to editors all
posting in registries of results of the same or closely related work.
Three years ago, trial registration was the exception; now it is the
rule. Registration facilitates the dissemination of information
among clinicians, researchers, and patients, and it helps to assure
trial participants that the information that accrues as a result of
their altruism will become part of the public record. The WHO’s
global efforts towards comprehensive trials registration and the
ICMJE’s requirements for registration aim to increase public trust
in medical science.
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